New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
07:59 EDTPRTAProthena data somewhat misunderstood by investors, says RBC Capital
RBC Capital believes the pullback in Prothena's stock reflected some misunderstanding of data on the company's NEOD001, a monoclonal antibody in clinical development for the treatment of patients with AL amyloidosis and persistent organ dysfunction. The firm believes that the data indicates that the drug is having a real impact. It keeps a $52 price target and Outperform rating on the stock.
News For PRTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
18:30 EDTPRTAOn The Fly: After Hours Movers
UP AFTER EARNINGS: VeriFone Systems (PAY), up 1.5%. ALSO HIGHER: Prothena (PRTA), up 10.7% after receiving FDA fast track designation for NEOD001... Boeing (BA), up 2.3% after increasing dividend by 25% and authorizing a $12B share repurchase plan... Yamana Gold (AUY), up 4.6% after reporting new discoveries at Chapada, El Penon. LOWER: Abraxas Petroleum (AXAS), down 2% after reporting fourth quarter volume guidance and fiscal 2015 production guidance.
16:09 EDTPRTAProthena receives FDA fast track designation for NEOD001
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use